Reappraisal of Transarterial Radioembolization for Liver-confined Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Editorial on "Transarterial Radioembolization Versus Tyrosine Kinase Inhibitor in Hepatocellular Carcinoma with Portal Vein...

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2024 Jul 17

PMID 39019082

Authors

Jin Hyoung Kim

Gun Ha Kim

Dong Il Gwon

Affiliations

Soon will be listed here.

References

Chow P, Gandhi M, Tan S, Khin M, Khasbazar A, Ong J . SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018; 36(19):1913-1921. DOI: 10.1200/JCO.2017.76.0892. View

. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022; 28(4):583-705. PMC: 9597235. DOI: 10.3350/cmh.2022.0294. View

Cho Y, Kim B, Park J . Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison. Clin Mol Hepatol. 2023; 29(2):252-262. PMC: 10121305. DOI: 10.3350/cmh.2023.0099. View

Hur M, Cho Y, Kim D, Lee J, Kim G, Kim H . Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol. 2023; 29(3):763-778. PMC: 10366806. DOI: 10.3350/cmh.2023.0076. View

Hwang H, Shim J, Kim J . Hepatocellular carcinoma with macrovascular invasion: need a personalized medicine for this complicated event. Hepatobiliary Surg Nutr. 2024; 13(1):188-190. PMC: 10839729. DOI: 10.21037/hbsn-23-653. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

Song D, Song M, Bae S, Chung W, Jang J, Kim Y . A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2014; 50(4):445-54. DOI: 10.1007/s00535-014-0978-3. View

Salem R, Lewandowski R, Mulcahy M, Riaz A, Ryu R, Ibrahim S . Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2009; 138(1):52-64. DOI: 10.1053/j.gastro.2009.09.006. View

Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, De Baere T . Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2020; 6(1):17-29. DOI: 10.1016/S2468-1253(20)30290-9. View

10.

Khan A, Wei X, Xu X . Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma. 2021; 8:1089-1115. PMC: 8434852. DOI: 10.2147/JHC.S318070. View

11.

Kulik L, Carr B, Mulcahy M, Lewandowski R, Atassi B, Ryu R . Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2007; 47(1):71-81. DOI: 10.1002/hep.21980. View

12.

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca A, Pageaux G . Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017; 18(12):1624-1636. DOI: 10.1016/S1470-2045(17)30683-6. View

13.

Bruix J, Cheng A, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J . Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017; 67(5):999-1008. DOI: 10.1016/j.jhep.2017.06.026. View

14.

Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C . Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol. 2018; 68(4):724-732. DOI: 10.1016/j.jhep.2017.12.026. View

15.

Hilgard P, Hamami M, El Fouly A, Scherag A, Muller S, Ertle J . Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010; 52(5):1741-9. DOI: 10.1002/hep.23944. View

16.

Yoon S, Lim Y, Won H, Kim J, Kim K, Lee H . Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys. 2011; 82(5):2004-11. DOI: 10.1016/j.ijrobp.2011.03.019. View

17.

Llovet J, Bustamante J, Castells A, Vilana R, Ayuso M, Sala M . Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1998; 29(1):62-7. DOI: 10.1002/hep.510290145. View

18.

Park J, Lee Y, Ko Y, Park Y, Shin H, Hur M . Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis. J Liver Cancer. 2024; 24(1):81-91. PMC: 10990665. DOI: 10.17998/jlc.2023.12.25. View